Synlait Milk shares rise 52% after key refinancing approved

Shares of Synlait Milk (ASX:SM1) jumped 52% after shareholders approved the first tier of a confusing refinancing of the troubled company’s debt and financials.

The stock jumped to a daily high of 38 cents before returning to around 34 cents after the shareholders’ meeting at a special meeting in New Zealand approved a $130 million loan deal. Zealand with the main Chinese shareholder, Bright Dairy.

The approval prevented the company from taking control early next week because Synlait didn’t have enough budget to repay the loan as its banks had demanded.

Shareholder approval of the loan agreement is mandatory because it is a similar party transaction with a major shareholder. This seemed in doubt earlier this week, when the second largest shareholder, a2 Milk, was slow to reveal how it would vote for its 19. 9%.

The two corporations have fallen out over an agreement Synlait entered into with a2, which is being terminated due to poor performance and other issues.

a2 revealed to the assembly that he would vote in favor of the Bright Dairy loan. This contributed to the increase in stocks and the approval gave new impetus.

The cash will be used to pay off a bank loan for the same amount that is due next Monday.

This will reduce debt, which stood at NZ$585 million at the end of May.

Synlait shareholders now have another meeting due later this year on the terms of a proposed retail factor and the refinancing of NZ$180 million of bank debt. Both deserve to be carried out at the same time.

The terms and amount of the factor will be announced early next month, with a new shareholders’ meeting in late August or early September, and the 2023-24 annual effects will be released at the end of the month. These numbers are not good.

Outlining Synlait’s long-term on Thursday, chairman George Adams said its purpose would be to raise capital over the next two months, but that it would be tricky as it seeks to raise capital equivalent to several times its current market price (about A$57 million). ).

Adams told Thursday’s meeting that the company is still reviewing its North Island operations, adding the future of its Pkeno plant, which will produce plant-based milks.

Synlait had tried unsuccessfully to sell the business of its client Dairyworks, owner of the Alpine and Rolling Meadow cheese brands, but ended the procedure after failing to obtain high enough offers.

He said Synlait would work between companies and its food service business, with its premium dairy products such as infant formulas.

Adams said a priority would be to check relations with a2 Milk.

Get updates delivered straight to your inbox.

Terms of Use | Privacy Policy | Contact | Show

 

Overall increases for Deep Leads resources: quality, tonnage and target area ABx Group has reported a 30% increase in its mineral resource estimate (MRE) at the rare Deep Leads ion adsorption clay (IAC) earth deposit Leads in northern Tasmania. The accumulation at MRE comes from 36 assayed extension wells, representing significant northward extension to the existing Deep Leads prospect.

Lake Resources (LKE. ASX) – LKE has signed two non-binding memorandums of understanding within 10 days. Ford Company (Ford) has signed a memorandum of understanding for about 25,000 t/year and last week, Hanwa, a Japanese commodity trader, signed a memorandum of understanding for up to 25,000 t/yr. Subject to execution, this is a feat as Ford and Hanwa are poised to collaborate on long-term strategic partnerships with LKE. Commercial negotiations are still ongoing but should, namely whether Ford and Hanwa will inject new capital into LKE, removing additional risks in financing the task and thus ensuring that LKE and Kachi are fully funded.

Two recent gravity studies have particularly exceeded expectations and revealed prospects for extension of the existing MRE at Throssell Lake, as well as a significant expansion opportunity at Yeo Lake. This reinforces the prospect of a multi-decade Tier 1 SOP production center around Lake Throssell.

TMG is currently completing work for the planned PFS in early 2023, adding start of drilling in Q3 2022, evaporation testing and permitting activities. The effects of those systems will affect the PFS and any long-term resource upgrades.

SOP reference prices have increased to around $940/t due to recent geopolitical developments. The October 2021 scoping study assumed an SOP value of $550/t and contained a sensitivity study showing that each 10% accrual in value effects amounted to $144 million accrued to the NPV of the $364 million allocation. The accrual of around 70% compared to the scoping study implies an NPV of the allocation of approximately $1. 4 billion.

Despite the fall in oil and fuel prices, which fell 5. 4% and 19. 7% respectively in August, Calima managed to show an improvement in its main indicators.

WT Financial Group Limited (WTL) is a rapidly growing diversified monetary company, founded in 2010 and indexed on the Australian Stock Exchange (ASX) in 2015. Its recommendations and product offerings are provided primarily through an advisory organization independent monetary advisors who act as legal advisors. representatives. WTL in relation to its broker organization activities Wealth Today Pty Ltd (Wealth Today) and Sentry Group Pty Ltd (Sentry Group). It has approximately 275 advisors in over two hundred money advice companies across Australia. It also operates a direct-to-consumer operation under its Spring Financial Group brand.

In May 2021, Corporate Connect analyst Marc Sinatra published a comprehensive research report on ASX-listed biotech Immutep Ltd (ASX: IMM). It was so inspired by IMM that Corporate Connect deemed it imperative to publish a follow-up report valuing the company, as the market did not see the great prospects for eftilagimod alfa (efti).

This monitoring report was published today. Using comparables, after adding a dollar reduction to its EV estimate and dividing by the total number of percentages issued, Corporate Connect now puts the fair price of one percentage of Immutep at A$2. 20.

Leave a Comment

Your email address will not be published. Required fields are marked *